Alexander M. Lesokhin, MD, is an Associate Attending Physician on the Myeloma Service and a member of the Ludwig Collaborative laboratory at Memorial Sloan Kettering Cancer Center in New York, New York.  He received his MD from the Albert Einstein College of Medicine with distinction in research.

Dr. Lesokhin’s research focuses on the ability of cancers to evade the immune system and on developing novel treatments to reverse this process.  He leads a portfolio of clinical trials testing the clinical and immune effects of antibodies targeting immune agonists, immune checkpoints, bi-specific engagers and adoptive cellular therapies for multiple myeloma.  He also leads studies evaluating the microbiome in association with treatment response and myeloma natural history.  He has additionally developed and validated assays for measuring myeloid-derived suppressor cells (MDSC) as a potential biomarker for efficacy of immune based therapies. His work has resulted in 80 peer-reviewed publications and 1 patent.  Dr. Lesokhin has received career development awards from the American Cancer Society and the Melanoma Research Alliance as well as funding from Cycle for Survival, the Sawiris Foundation, the Parker Institute for Cancer Immunotherapy and the Paula and Rodger Riney Family Foundation.